LICENSE AGREEMENTS (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
LICENSE AGREEMENTS (Details) - USD ($) $ in Millions	Jun. 30, 2026	Feb. 28, 2023	Jun. 30, 2026
XOMA (US) LLC \| Ersodetug License Agreement [Member]
LICENSE AGREEMENTS
Milestone Payments	$ 12.0		$ 12.0
XOMA (US) LLC \| Ersodetug License Agreement [Member] \| After Clinical and Regulatory Milestones \| Maximum
LICENSE AGREEMENTS
Maximum additional milestone payments	185.0		185.0
XOMA (US) LLC \| US Clinical Trial Rz358 (ersodetug) \| Ersodetug License Agreement [Member] \| Upon Regulatory Approval
LICENSE AGREEMENTS
Milestone closing payment			25.0
XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 (ersodetug) \| Ersodetug License Agreement [Member]
LICENSE AGREEMENTS
Milestone closing payment	5.0
ActiveSite Pharmaceuticals, Inc \| Clinical Trial Rz 402 \| Development And License Agreement
LICENSE AGREEMENTS
Milestone Payments	4.0		$ 4.0
ActiveSite Pharmaceuticals, Inc \| Clinical Trial Rz 402 \| Development And License Agreement \| Scenario, Plan
LICENSE AGREEMENTS
Royalties percentage			2.00%
ActiveSite Pharmaceuticals, Inc \| Clinical Trial Rz 402 \| Development And License Agreement \| Scenario, Plan \| Maximum
LICENSE AGREEMENTS
Maximum additional milestone payments	$ 42.5		$ 42.5
ActiveSite Pharmaceuticals, Inc \| Phase 2 Clinical Trial RZ402 \| Development And License Agreement
LICENSE AGREEMENTS
Milestone closing payment		$ 3.0
ActiveSite Pharmaceuticals, Inc \| Phase 3 Clinical Trial RZ 402 \| Development And License Agreement \| Scenario, Upon First Dosing Of The First Patient
LICENSE AGREEMENTS
Milestone closing payment			$ 5.0